157 related articles for article (PubMed ID: 30413194)
1. Epidermal growth factor expression as a predictor of chemotherapeutic resistance in muscle-invasive bladder cancer.
Mansour AM; Abdelrahim M; Laymon M; Elsherbeeny M; Sultan M; Shokeir A; Mosbah A; Abol-Enein H; Awadalla A; Cho E; Sairam V; Park TD; Shahid M; Kim J
BMC Urol; 2018 Nov; 18(1):100. PubMed ID: 30413194
[TBL] [Abstract][Full Text] [Related]
2. S100A9 and EGFR gene signatures predict disease progression in muscle invasive bladder cancer patients after chemotherapy.
Kim WT; Kim J; Yan C; Jeong P; Choi SY; Lee OJ; Chae YB; Yun SJ; Lee SC; Kim WJ
Ann Oncol; 2014 May; 25(5):974-9. PubMed ID: 24631944
[TBL] [Abstract][Full Text] [Related]
3. FGFR3 overexpression is prognostic of adverse outcome for muscle-invasive bladder carcinoma treated with adjuvant chemotherapy.
Sung JY; Sun JM; Chang Jeong B; Il Seo S; Soo Jeon S; Moo Lee H; Yong Choi H; Young Kang S; Choi YL; Young Kwon G
Urol Oncol; 2014 Jan; 32(1):49.e23-31. PubMed ID: 24360661
[TBL] [Abstract][Full Text] [Related]
4. Epidermal Growth Factor Receptor (EGFR) Cell Expression During Adjuvant Treatment After Transurethral Resection for Non-Muscle-Invasive Bladder Cancer: A New Potential Tool to Identify Patients at Higher Risk of Disease Progression.
Di Maida F; Mari A; Scalici Gesolfo C; Cangemi A; Allegro R; Sforza S; Cocci A; Tellini R; Masieri L; Russo A; Carini M; Minervini A; Serretta V
Clin Genitourin Cancer; 2019 Aug; 17(4):e751-e758. PubMed ID: 31126772
[TBL] [Abstract][Full Text] [Related]
5. Epidermal growth factor receptor status predicts local response to radical radiotherapy in muscle-invasive bladder cancer.
Colquhoun AJ; Sundar S; Rajjayabun PH; Griffiths TR; Symonds RP; Mellon JK
Clin Oncol (R Coll Radiol); 2006 Nov; 18(9):702-9. PubMed ID: 17100158
[TBL] [Abstract][Full Text] [Related]
6. Impact of adjuvant chemotherapy in patients with adverse features and variant histology at radical cystectomy for muscle-invasive carcinoma of the bladder: Does histologic subtype matter?
Berg S; D'Andrea D; Vetterlein MW; Cole AP; Fletcher SA; Krimphove MJ; Marchese M; Lipsitz SR; Sonpavde G; Noldus J; Shariat SF; Kibel AS; Trinh QD; Mossanen M
Cancer; 2019 May; 125(9):1449-1458. PubMed ID: 30620387
[TBL] [Abstract][Full Text] [Related]
7. The Nrf2 transcription factor contributes to resistance to cisplatin in bladder cancer.
Hayden A; Douglas J; Sommerlad M; Andrews L; Gould K; Hussain S; Thomas GJ; Packham G; Crabb SJ
Urol Oncol; 2014 Aug; 32(6):806-14. PubMed ID: 24837013
[TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of adjuvant cisplatin-based combination chemotherapy following radical cystectomy in patients with invasive bladder cancer.
Muramaki M; Miyake H; Kurahashi T; Takenaka A; Inoue TA; Fujisawa M
Int J Urol; 2008 Apr; 15(4):314-8. PubMed ID: 18380818
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness of Adjuvant Chemotherapy After Radical Cystectomy for Locally Advanced and/or Pelvic Lymph Node-Positive Muscle-invasive Urothelial Carcinoma of the Bladder: A Propensity Score-Weighted Competing Risks Analysis.
Vetterlein MW; Seisen T; May M; Nuhn P; Gierth M; Mayr R; Fritsche HM; Burger M; Novotny V; Froehner M; Wirth MP; Protzel C; Hakenberg OW; Roghmann F; Palisaar RJ; Noldus J; Pycha A; Bastian PJ; Trinh QD; Xylinas E; Shariat SF; Rink M; Chun FK; Dahlem R; Fisch M; Aziz A;
Eur Urol Focus; 2018 Mar; 4(2):252-259. PubMed ID: 28753775
[TBL] [Abstract][Full Text] [Related]
10. The effect of cystectomy, and perioperative methotrexate, vinblastine, doxorubicin and cisplatin chemotherapy on the risk and pattern of relapse in patients with muscle invasive bladder cancer.
Ennis RD; Petrylak DP; Singh P; Bagiella E; O'Toole KM; Benson MC; Olsson CA
J Urol; 2000 May; 163(5):1413-8. PubMed ID: 10751847
[TBL] [Abstract][Full Text] [Related]
11. Triple-marker immunohistochemical assessment of muscle-invasive bladder cancer: Is there prognostic significance?
Labban M; Najdi J; Mukherji D; Abou-Kheir W; Tabbarah A; El-Hajj A
Cancer Rep (Hoboken); 2021 Apr; 4(2):e1313. PubMed ID: 33538412
[TBL] [Abstract][Full Text] [Related]
12. ErbB2 and NFκB overexpression as predictors of chemoradiation resistance and putative targets to overcome resistance in muscle-invasive bladder cancer.
Koga F; Yoshida S; Tatokoro M; Kawakami S; Fujii Y; Kumagai J; Neckers L; Kihara K
PLoS One; 2011; 6(11):e27616. PubMed ID: 22102915
[TBL] [Abstract][Full Text] [Related]
13. Urothelial carcinoma in situ response to cisplatin-based neoadjuvant chemotherapy, or lack thereof: Impact on patient selection for organ preservation in muscle-invasive disease?
Tachibana I; Bandali E; Calaway AC; Krishnan N; Cheng L; Adra N; Kaimakliotis HZ
Urol Oncol; 2020 Nov; 38(11):850.e1-850.e7. PubMed ID: 32693973
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness of platinum-based adjuvant chemotherapy for muscle-invasive bladder cancer: A weighted propensity score analysis.
Shimizu F; Muto S; Taguri M; Ieda T; Tsujimura A; Sakamoto Y; Fujita K; Okegawa T; Yamaguchi R; Horie S
Int J Urol; 2017 May; 24(5):367-372. PubMed ID: 28281310
[TBL] [Abstract][Full Text] [Related]
15. Oncological outcomes of concomitant carcinoma in situ at radical cystectomy in pure urothelial bladder cancer and in histological variants.
Naspro R; La Croce G; Finati M; Roscigno M; Pellucchi F; Sodano M; Manica M; Gianatti A; Da Pozzo LF
Urol Oncol; 2022 Feb; 40(2):61.e9-61.e19. PubMed ID: 34334293
[TBL] [Abstract][Full Text] [Related]
16. Absence of Tumor on Repeat Transurethral Resection of Bladder Tumor Does Not Predict Final Pathologic T0 Stage in Bladder Cancer Treated with Radical Cystectomy.
Kukreja JB; Porten S; Golla V; Ho PL; Noguera-Gonzalez G; Navai N; Kamat AM; Dinney CPN; Shah JB
Eur Urol Focus; 2018 Sep; 4(5):720-724. PubMed ID: 28753837
[TBL] [Abstract][Full Text] [Related]
17. Impact of High-risk Features and Effect of Neoadjuvant Chemotherapy in Urothelial Cancer Patients with Invasion into the Lamina Propria on Transurethral Resection in the Absence of Deep Muscle Invasion.
Metcalfe MJ; Ferguson JE; Li R; Xiao L; Guo CC; Czerniak BA; Siefker-Radtke A; Pretzsch SM; Navai N; McConkey DJ; Kamat AM; Campbell M; Dinney C
Eur Urol Focus; 2017 Dec; 3(6):577-583. PubMed ID: 28753816
[TBL] [Abstract][Full Text] [Related]
18. D2-40/podoplanin expression in cancer stroma by immunohistochemical staining is associated with poor prognosis in bladder cancer patients after radical cystectomy.
Okajima E; Tomizawa M; Shimada K; Negishi T; Nishiyama N; Kitamura H
Urol Oncol; 2020 Oct; 38(10):797.e7-797.e13. PubMed ID: 32576528
[TBL] [Abstract][Full Text] [Related]
19. Expression of the epidermal growth factor receptor and Her-2 are predictors of favorable outcome and reduced complete response rates, respectively, in patients with muscle-invading bladder cancers treated by concurrent radiation and cisplatin-based chemotherapy: a report from the Radiation Therapy Oncology Group.
Chakravarti A; Winter K; Wu CL; Kaufman D; Hammond E; Parliament M; Tester W; Hagan M; Grignon D; Heney N; Pollack A; Sandler H; Shipley W
Int J Radiat Oncol Biol Phys; 2005 Jun; 62(2):309-17. PubMed ID: 15890569
[TBL] [Abstract][Full Text] [Related]
20. SNAI1 protein expression is an independent negative prognosticator in muscle-invasive bladder cancer.
Keck B; Wach S; Goebell PJ; Kunath F; Bertz S; Lehmann J; Stöckle M; Taubert H; Wullich B; Hartmann A
Ann Surg Oncol; 2013 Oct; 20(11):3669-74. PubMed ID: 23807662
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
